A Pragmatic Approach Using First-Principle Methods to Address Site of Metabolism with Implications for Reactive Metabolite Formation

A majority of xenobiotics are metabolized by cytochrome P450 (CYP) enzymes. The discovery of drug candidates with low propensity to form reactive metabolites and low clearance can be facilitated by understanding CYP-mediated xenobiotic metabolism. Being able to predict the sites where reactive metabolites form is beneficial in drug design to produce drug candidates free of reactive metabolite issues. Herein, we report a pragmatic protocol using first-principle density functional theory (DFT) calculations for predicting sites of epoxidation and hydroxylation of aromatic substrates mediated by CYP. The method is based on the relative stabilities of the CYP-substrate intermediates or the substrate epoxides. Consequently, it concerns mainly the electronic reactivity of the substrates. Comparing to the experimental findings, the presented protocol gave excellent first-ranked epoxidation site predictions of 83%, and when the test was extended to CYP-mediated sites of aromatic hydroxylation, satisfactory results were also obtained (73%). This indicates that our assumptions are valid and also implies that the intrinsic reactivities of the substrates are in general more important than their binding poses in proteins, although the protocol may benefit from the addition of docking information.

[1]  S. Born,et al.  Identification of the cytochromes P450 that catalyze coumarin 3,4-epoxidation and 3-hydroxylation. , 2002, Drug metabolism and disposition: the biological fate of chemicals.

[2]  Angus Nedderman,et al.  In vitro screening techniques for reactive metabolites for minimizing bioactivation potential in drug discovery. , 2008, Current drug metabolism.

[3]  P M Shaw,et al.  Different contributions of cytochrome P450 2C19 and 3A4 in the oxidation of omeprazole by human liver microsomes: effects of contents of these two forms in individual human samples. , 1997, The Journal of pharmacology and experimental therapeutics.

[4]  R. Tukey,et al.  Propranolol 4- and 5-hydroxylation and N-desisopropylation by cloned human cytochrome P4501A1 and P4501A2. , 1996, Drug metabolism and disposition: the biological fate of chemicals.

[5]  Ping Zhao,et al.  HUMAN IN VITRO GLUTATHIONYL AND PROTEIN ADDUCTS OF CARBAMAZEPINE-10,11-EPOXIDE, A STABLE AND PHARMACOLOGICALLY ACTIVE METABOLITE OF CARBAMAZEPINE , 2005, Drug Metabolism and Disposition.

[6]  H. Yamazaki,et al.  Prediction of human liver microsomal oxidations of 7-ethoxycoumarin and chlorzoxazone with kinetic parameters of recombinant cytochrome P-450 enzymes. , 1999, Drug metabolism and disposition: the biological fate of chemicals.

[7]  R. Subramanian,et al.  Bioactivation of a Novel 2-Methylindole-Containing Dual Chemoattractant Receptor-Homologous Molecule Expressed on T-Helper Type-2 Cells/d-Prostanoid Receptor Antagonist Leads to Mechanism-Based CYP3A Inactivation: Glutathione Adduct Characterization and Prediction of In Vivo Drug-Drug Interaction , 2010, Drug Metabolism and Disposition.

[8]  T Ishizaki,et al.  Reappraisal of human CYP isoforms involved in imipramine N-demethylation and 2-hydroxylation: a study using microsomes obtained from putative extensive and poor metabolizers of S-mephenytoin and eleven recombinant human CYPs. , 1997, The Journal of pharmacology and experimental therapeutics.

[9]  F. Guengerich,et al.  Human cytochromes P4501A1 and P4501A2: R-warfarin metabolism as a probe. , 1995, Drug metabolism and disposition: the biological fate of chemicals.

[10]  P. C. Hariharan,et al.  The influence of polarization functions on molecular orbital hydrogenation energies , 1973 .

[11]  George S. Hammond,et al.  A Correlation of Reaction Rates , 1955 .

[12]  H. Yamazaki,et al.  Bufuralol hydroxylation by cytochrome P450 2D6 and 1A2 enzymes in human liver microsomes. , 1994, Molecular pharmacology.

[13]  Thomas Walle,et al.  Oxidation of the flavonoids galangin and kaempferide by human liver microsomes and CYP1A1, CYP1A2, and CYP2C9. , 2002, Drug metabolism and disposition: the biological fate of chemicals.

[14]  S. Shaik,et al.  Alkane Hydroxylation by Cytochrome P450: Is Kinetic Isotope Effect a Reliable Probe of Transition State Structure? , 2000 .

[15]  Y Ohno,et al.  Metabolic activation of o-phenylphenol to a major cytotoxic metabolite, phenylhydroquinone: role of human CYP1A2 and rat CYP2C11/CYP2E1 , 2000, Xenobiotica; the fate of foreign compounds in biological systems.

[16]  D. Morin,et al.  Glutathione conjugation of electrophilic metabolites of 1-nitronaphthalene in rat tracheobronchial airways and liver: identification by mass spectrometry and proton nuclear magnetic resonance spectroscopy. , 1999, Chemical research in toxicology.

[17]  J. Sutra,et al.  Identification of human and rabbit cytochromes P450 1A2 as major isoforms involved in thiabendazole 5‐hydroxylation , 1998, Fundamental & clinical pharmacology.

[18]  R J Edwards,et al.  Determination of human hepatic cytochrome P4501A2 activity in vitro use of tacrine as an isoenzyme-specific probe. , 1995, Drug metabolism and disposition: the biological fate of chemicals.

[19]  Chris Oostenbrink,et al.  Fast Prediction of Cytochrome P450 Mediated Drug Metabolism , 2009, ChemMedChem.

[20]  G Ekström,et al.  Ropivacaine, a new amide-type local anesthetic agent, is metabolized by cytochromes P450 1A and 3A in human liver microsomes. , 1996, Drug metabolism and disposition: the biological fate of chemicals.

[21]  Hao Chen,et al.  Bioactivation of lamotrigine in vivo in rat and in vitro in human liver microsomes, hepatocytes, and epidermal keratinocytes: characterization of thioether conjugates by liquid chromatography/mass spectrometry and high field nuclear magnetic resonance spectroscopy. , 2010, Chemical research in toxicology.

[22]  S Ohmori,et al.  Cytochrome P450 isozymes involved in propranolol metabolism in human liver microsomes. The role of CYP2D6 as ring-hydroxylase and CYP1A2 as N-desisopropylase. , 1994, Drug metabolism and disposition: the biological fate of chemicals.

[23]  P. Beaune,et al.  Cytochrome P4502C9 is the principal catalyst of racemic acenocoumarol hydroxylation reactions in human liver microsomes. , 2000, Drug metabolism and disposition: the biological fate of chemicals.

[24]  T Yamamoto,et al.  Involvement of CYP1A2 in mexiletine metabolism. , 1998, British journal of clinical pharmacology.

[25]  M. Myers,et al.  Role of cytochrome P450 IA2 in acetanilide 4-hydroxylation as determined with cDNA expression and monoclonal antibodies. , 1991, Archives of biochemistry and biophysics.

[26]  B. Lee,et al.  The interpretation of protein structures: estimation of static accessibility. , 1971, Journal of molecular biology.

[27]  S. Wrighton,et al.  Role of cytochrome P450 2C9 and an allelic variant in the 4'-hydroxylation of (R)- and (S)-flurbiprofen. , 1995, Biochemical pharmacology.

[28]  Michael Zientek,et al.  Mechanism-Based Inactivation of Cytochrome P450 2C9 by Tienilic Acid and (±)-Suprofen: A Comparison of Kinetics and Probe Substrate Selection , 2009, Drug Metabolism and Disposition.

[29]  H. DeLuca,et al.  Isolation and identification of 5, 6-epoxyretinoic acid: a biologically active metabolite of retinoic acid. , 1978, Biochemistry.

[30]  W. Trager,et al.  Mechanism-based inactivation of cytochrome P450 2B1 by 8-methoxypsoralen and several other furanocoumarins. , 1998, Biochemistry.

[31]  T. Shimada,et al.  Lidocaine metabolism by human cytochrome P-450s purified from hepatic microsomes: comparison of those with rat hepatic cytochrome P-450s. , 1990, The Journal of pharmacology and experimental therapeutics.

[32]  S K Balani,et al.  In vitro studies on the metabolic activation of the furanopyridine L-754,394, a highly potent and selective mechanism-based inhibitor of cytochrome P450 3A4. , 1996, Chemical research in toxicology.

[33]  M. Odomi,et al.  Biotransformation of the novel inotropic agent toborinone (OPC-18790) in rats and dogs. Evidence for the formation of novel glutathione and two cysteine conjugates. , 1997, Drug metabolism and disposition: the biological fate of chemicals.

[34]  Lars Ridder,et al.  Mechanism and structure-reactivity relationships for aromatic hydroxylation by cytochrome P450. , 2004, Organic & biomolecular chemistry.

[35]  Ilme Schlichting,et al.  Structure and chemistry of cytochrome P450. , 2005, Chemical reviews.

[36]  J E Leffler,et al.  Parameters for the Description of Transition States. , 1953, Science.

[37]  Mark Kao,et al.  Metabolism and Excretion of RWJ-333369 [1,2-Ethanediol, 1-(2-Chlorophenyl)-, 2-carbamate, (S)-] in Mice, Rats, Rabbits, and Dogs , 2007, Drug Metabolism and Disposition.

[38]  J P Perdrix,et al.  Possible involvement of multiple human cytochrome P450 isoforms in the liver metabolism of propofol. , 1998, British journal of anaesthesia.

[39]  K. Uchino,et al.  Oxidative metabolism of flunarizine and cinnarizine by microsomes from B-lymphoblastoid cell lines expressing human cytochrome P450 enzymes. , 1996, Biological & pharmaceutical bulletin.

[40]  S. Born,et al.  Synthesis and reactivity of coumarin 3,4-epoxide. , 1997, Drug metabolism and disposition: the biological fate of chemicals.

[41]  Mark S. Gordon,et al.  Self‐consistent molecular orbital methods. XXIII. A polarization‐type basis set for second‐row elements , 1982 .

[42]  D. Swinney,et al.  Isotopically labeled chlorobenzenes as probes for the mechanism of cytochrome P-450 catalyzed aromatic hydroxylation. , 1989, Biochemistry.

[43]  A. D. Rodrigues,et al.  Identification of the human liver cytochrome P450 enzymes involved in the metabolism of zileuton (ABT-077) and its N-dehydroxylated metabolite, Abbott-66193. , 1995, Drug metabolism and disposition: the biological fate of chemicals.

[44]  S Udenfriend,et al.  Hydroxylation-induced migration: the NIH shift. Recent experiments reveal an unexpected and general result of enzymatic hydroxylation of aromatic compounds. , 1967, Science.

[45]  P Koch,et al.  Biological fate of sirdalud in animals and man. , 1989, Xenobiotica; the fate of foreign compounds in biological systems.

[46]  U. Hofmann,et al.  Antipyrine as a probe for human oxidative drug metabolism: Identification of the cytochrome P450 enzymes catalyzing 4‐hydroxyantipyrine, 3‐hydroxymethylantipyrine, and norantipyrine formation , 1996, Clinical pharmacology and therapeutics.

[47]  A. Somogyi,et al.  Comparison of (S)-mephenytoin and proguanil oxidation in vitro: contribution of several CYP isoforms. , 1999, British journal of clinical pharmacology.

[48]  J. Pople,et al.  Self—Consistent Molecular Orbital Methods. XII. Further Extensions of Gaussian—Type Basis Sets for Use in Molecular Orbital Studies of Organic Molecules , 1972 .

[49]  Xiaochao Ma,et al.  METABOLISM OF MELATONIN BY HUMAN CYTOCHROMES P450 , 2005, Drug Metabolism and Disposition.

[50]  H Chen,et al.  Characterization of novel glutathione adducts of a non-nucleoside reverse transcriptase inhibitor, (S)-6-chloro-4-(cyclopropylethynyl)-4-(trifluoromethyl)-3, 4-dihydro-2(1H)-quinazolinone (DPC 961), in rats. Possible formation of an oxirene metabolic intermediate from a disubstituted alkyne. , 2000, Chemical research in toxicology.

[51]  Ákos Tarcsay,et al.  In silico site of metabolism prediction of cytochrome P450-mediated biotransformations , 2011, Expert opinion on drug metabolism & toxicology.

[52]  R. Straka,et al.  Evaluation of the Influence of Diabetes Mellitus on Antipyrine Metabolism and CYP1A2 and CYP2D6 Activity , 2000, Pharmacotherapy.

[53]  Collaborative Computational,et al.  The CCP4 suite: programs for protein crystallography. , 1994, Acta crystallographica. Section D, Biological crystallography.

[54]  D. Mansuy,et al.  Diclofenac and its derivatives as tools for studying human cytochromes P450 active sites: particular efficiency and regioselectivity of P450 2Cs. , 1999, Biochemistry.

[55]  G. Doss,et al.  IDENTIFICATION AND METABOLISM OF A NOVEL DIHYDROHYDROXY-S-GLUTATHIONYL CONJUGATE OF A PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR AGONIST, MK-0767 [(±)-5-[(2,4-DIOXOTHIAZOLIDIN-5-YL)METHYL]-2-METHOXY-N-[[(4-TRIFLUOROMETHYL) PHENYL]METHYL]BENZAMIDE], IN RATS , 2004, Drug Metabolism and Disposition.

[56]  A. Becke Density-functional thermochemistry. III. The role of exact exchange , 1993 .

[57]  H K Kroemer,et al.  Influence of debrisoquine phenotype and of quinidine on mexiletine disposition in man. , 1991, The Journal of pharmacology and experimental therapeutics.

[58]  J. Bloomer,et al.  In vitro identification of the P450 enzymes responsible for the metabolism of ropinirole. , 1997, Drug metabolism and disposition: the biological fate of chemicals.

[59]  David C Evans,et al.  EVIDENCE FOR THE BIOACTIVATION OF ZOMEPIRAC AND TOLMETIN BY AN OXIDATIVE PATHWAY: IDENTIFICATION OF GLUTATHIONE ADDUCTS IN VITRO IN HUMAN LIVER MICROSOMES AND IN VIVO IN RATS , 2006, Drug Metabolism and Disposition.

[60]  Liang-Shang Gan,et al.  Bioactivation of benzylamine to reactive intermediates in rodents: formation of glutathione, glutamate, and peptide conjugates. , 2002, Chemical research in toxicology.

[61]  Jia-Sheng Wang,et al.  Efficient activation of aflatoxin B1 by cytochrome P450 2A13, an enzyme predominantly expressed in human respiratory tract , 2006, International journal of cancer.

[62]  Michael M. Mysinger,et al.  Computational models for cytochrome P450: a predictive electronic model for aromatic oxidation and hydrogen atom abstraction. , 2002, Drug metabolism and disposition: the biological fate of chemicals.

[63]  Gerald T Miwa,et al.  Bioactivation of drugs: risk and drug design. , 2011, Annual review of pharmacology and toxicology.

[64]  Chul-Ho Yun,et al.  Kinetic deuterium isotope effects for 7‐alkoxycoumarin O‐dealkylation reactions catalyzed by human cytochromes P450 and in liver microsomes , 2006, The FEBS journal.

[65]  Julian Blagg,et al.  The Metabolism and Toxicity of Furosemide in the Wistar Rat and CD-1 Mouse: a Chemical and Biochemical Definition of the Toxicophore , 2007, Journal of Pharmacology and Experimental Therapeutics.

[66]  Lars Olsen,et al.  Prediction of activation energies for hydrogen abstraction by cytochrome p450. , 2006, Journal of medicinal chemistry.

[67]  S. Clarke,et al.  In vitro identification of the human cytochrome P450 enzymes involved in the metabolism of R(+)- and S(-)-carvedilol. , 1997, Drug metabolism and disposition: the biological fate of chemicals.

[68]  Parr,et al.  Development of the Colle-Salvetti correlation-energy formula into a functional of the electron density. , 1988, Physical review. B, Condensed matter.

[69]  R. Hanzlik,et al.  Premercapturic acid metabolites of bromobenzene derived via its 2,3- and 3,4-oxide metabolites. , 1991, Xenobiotica; the fate of foreign compounds in biological systems.

[70]  Liang-Shang Gan,et al.  Disposition of 1-[3-(aminomethyl)phenyl]-N-[3-fluoro-2'- (methylsulfonyl)-[1,1'-biphenyl]-4-yl]-3-(trifluoromethyl)- 1H-pyrazole-5-carboxamide (DPC 423) by novel metabolic pathways. Characterization of unusual metabolites by liquid chromatography/mass spectrometry and NMR. , 2002, Chemical research in toxicology.

[71]  M. Bialer,et al.  The Absorption, Metabolism, and Excretion of the Novel Neuromodulator RWJ-333369 (1,2-Ethanediol, [1-2-Chlorophenyl]-, 2-carbamate, [S]-) in Humans , 2007, Drug Metabolism and Disposition.

[72]  S Udenfriend,et al.  The role of arene oxide-oxepin systems in the metabolism of aromatic substrates. 3. Formation of 1,2-naphthalene oxide from naphthalene by liver microsomes. , 1968, Journal of the American Chemical Society.

[73]  Gildas Bertho,et al.  First evidence that cytochrome P450 may catalyze both S-oxidation and epoxidation of thiophene derivatives. , 2005, Biochemical and biophysical research communications.

[74]  T. Baillie,et al.  Metabolic activation of a pyrazinone-containing thrombin inhibitor. Evidence for novel biotransformation involving pyrazinone ring oxidation, rearrangement, and covalent binding to proteins. , 2003, Chemical research in toxicology.

[75]  J. Tomasi,et al.  Quantum mechanical continuum solvation models. , 2005, Chemical reviews.

[76]  Lars Olsen,et al.  Prediction of activation energies for aromatic oxidation by cytochrome P450. , 2008, The journal of physical chemistry. A.

[77]  Chun Xing Li,et al.  In vitro metabolism of the COX-2 inhibitor DFU, including a novel glutathione adduct rearomatization. , 2001, Drug metabolism and disposition: the biological fate of chemicals.

[78]  Liang-Shang Gan,et al.  Delineating novel metabolic pathways of DPC 963, a non-nucleoside reverse transcriptase inhibitor, in rats. Characterization of glutathione conjugates of postulated oxirene and benzoquinone imine intermediates by LC/MS and LC/NMR. , 2002, Chemical research in toxicology.

[79]  T. Aoyama,et al.  Hydroxylation of warfarin by human cDNA-expressed cytochrome P-450: a role for P-4502C9 in the etiology of (S)-warfarin-drug interactions. , 1992, Chemical research in toxicology.

[80]  Zeruesenay Desta,et al.  Characterization of human cytochrome P450 enzymes catalyzing domperidone N-dealkylation and hydroxylation in vitro. , 2004, British journal of clinical pharmacology.

[81]  D. Mansuy,et al.  The substrate binding site of human liver cytochrome P450 2C9: an approach using designed tienilic acid derivatives and molecular modeling. , 1995, Biochemistry.

[82]  Vijay T. Ahuja,et al.  Comparative Biotransformation of Pyrazinone-Containing Corticotropin-Releasing Factor Receptor-1 Antagonists: Minimizing the Reactive Metabolite Formation , 2010, Drug Metabolism and Disposition.

[83]  Jeremy N. Harvey,et al.  QM/MM modeling of benzene hydroxylation in human cytochrome P450 2C9. , 2008, The journal of physical chemistry. A.

[84]  Yan Li,et al.  Risk assessment and mitigation strategies for reactive metabolites in drug discovery and development. , 2011, Chemico-biological interactions.

[85]  A Boobis,et al.  Hepatic metabolism of diclofenac: role of human CYP in the minor oxidative pathways. , 1999, Biochemical pharmacology.